Squamous cell carcinoma of the head and neck

Keytruda Breaks New Ground with FDA Approval for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

1 week ago talkbio0Tagged Adjuvant Therapy, Approved, Clinical Trials, Event-Free Survival, Gene Expression, KEYNOTE-689 trial, Keytruda, Neoadjuvant Therapy, PD-L1, pembrolizumab, perioperative, Squamous cell carcinoma of the head and neck, United States Food and Drug Administration

Keytruda; pembrolizumab; perioperative treatment; head and neck squamous cell carcinoma; HNSCC; FDA approval; KEYNOTE-689 trial; neoadjuvant therapy; adjuvant therapy; PD-L1 expression; event-free survival; clinical trial

Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset

1 year ago talkbio0Tagged Clinical Trials, Congress (U.S. Legislature), ESMO, Head, Malignant Neoplasms, Merus, MRUS, N.V., Petosemtamab, Squamous cell carcinoma of the head and neck

Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024

IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck

1 year ago talkbio0Tagged biotech, Cancer Vaccines, Head and neck structure, Immunotherapy, Io satellite, IO102-IO103, Keytruda, pembrolizumab, Phase 2 trial, Squamous cell carcinoma, Squamous cell carcinoma of the head and neck

IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy